Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)

Not Applicable

Terminated

Conditions: Tumors, Breast
Breast Cancer

Interventions: Device: DBT and FFDM

Registration Number: NCT02324205

Lead Sponsor: GE Healthcare

Brief Summary: The aim of this recruitment plan (ADAPT-BX) is to collect image and technical data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM), along with other subject data including histology results from biopsy specimen examination and cancer classification data from initially asymptomatic women referred for biopsy after recall from screening and diagnostic work-up. These data will be included in a subsequent and prospectively planned pooled analysis described in a separate protocol (ADAPT-BIE) examining superiority of DBT to FFDM for breast cancer diagnosis and other clinical performance measures.

Detailed Description: ADAPT program consists of 2 recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.

Recruitment & Eligibility

Status: TERMINATED

Sex: Female

Target Recruitment: 196

Inclusion Criteria

Women aged 30 years or older (≥30 years old);
Initially asymptomatic women that underwent routine screening FFDM, breast ultrasound (U/S), breast magnetic resonance imaging (MRI) and/or DBT, followed by diagnostic work-up showing one of more abnormalities and referred for breast biopsy within of 30 days before study entry;
Are able and willing to comply with study procedures;
Have signed and dated the informed consent form;
Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.

Exclusion Criteria

Have been previously included in this study;
Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging;
Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during a DBT examination (or FFDM, if required);
Have participated in (within the prior 30 days), another trial of an investigational product expected to interfere with study procedures or outcomes;
Have breast implant(s);
Have reconstructed breast(s).

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
DBT and FFDM	DBT and FFDM	Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.

Primary Outcome Measures

Name	Time	Method
Number of Participants With DBT, FFDM and Biopsy Specimens Collected.	Approximately 8 weeks	For each participant, obtain image data using two methods (DBT and FFDM) and obtain histology results of biopsy specimens from women referred for biopsy.

Secondary Outcome Measures

Name	Time	Method
Lesion Type Observed by DBT Imaging	Approximately 8 weeks	Lesions were characterized based on findings identified during image evaluations performed by qualified researchers.
Biopsy Finding of Lesions Per Subject.	Approximately 8 weeks	Describes histologic cancer and non-cancer findings of lesion biopsy. Cancer status of lesions was reported per subject, not per lesion.
Lesion Type Observed by FFDM Imaging	Approximately 8 weeks	Lesions were characterized based on findings identified during image evaluations performed by qualified readers.
Maximum Lesion Dimension as Observed by DBT	Approximately 8 weeks	Maximum length of lesions (measured in mm) when images were collected using DBT
Maximum Lesion Dimension as Observed by FFDM	Approximately 8 weeks	Maximum Length of Lesions (measured in mm) when images were collected using FFDM.

Trial Locations

Locations (3): Boca Raton Regional Hospital Christine E. Lynn Women's Health and Wellness Institute
🇺🇸
Boca Raton, Florida, United States
Cooper Health - Cooper Breast Imaging Centers
🇺🇸
Voorhees, New Jersey, United States
Gustave Roussy
🇫🇷
Villejuif, France